Organon & Co. (NYSE:OGN) stated that the recommendation highlights the cream’s status as a steroid-free and effective option for daily disease management. It does not have precautions or label ...

Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

While some topical herbal therapies may provide benefit for patients with AD, systemic herbal therapies do not provide significant benefit.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc.

Until having two children who suffer from eczema, I hadn't experienced the condition first-hand, and so hadn't realised how ...

A recent study reveals that a novel postbiotic supplement, Pet Immune, significantly alleviates itching and enhances skin and ...